Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Anteris Technologies.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Probiotics supplier has gut feeling about surging growth
Health & Biotech
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq
Health & Biotech
ASX medtechs at heart of growing cardiac care market
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
Health & Biotech
Beyond resources: WA aims to be medical and life sciences powerhouse
Health & Biotech
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Health & Biotech
With FDA approval close, Echo IQ’s AI platform is set to disrupt US heart disease market
Health & Biotech
ASX medtechs poised to transform healthcare with upcoming catalysts in 2024 – Part 2
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Anteris Technologies is leading a heart condition treatment revolution
Health & Biotech
FDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: It certainly wasn’t cricket as Monday markets in Australia knocked right back to last year
Health & Biotech
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Health & Biotech
ASX Health Stocks: Anteris successfully implants aortic valve, MGC Pharma a step closer to FDA submission
Health & Biotech
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
News
